% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan May 30, 2013 12:41 AM Flag

    Today's presentation by Vertex CEOl, Jeff Leiden at Berstein conference

    Well worth listening to both his prepared remarks and the Q&A. Geoff Porges asked very good questions and they were all answered well by Dr. Leiden. They stock should regain momentum as the clinical data that will be released throughout the remainder of this year and into 2014 gets appreciated. Starting with CF data mentioned to be released next month at ECFS conference in Lisbon, and the Phase 3 770 monotherapy data and Phase 2 VX 135 and VX 509 data to be released in the second half of this year, and of course the Phase 3 809/770 data next year. The company will be licensing VX 787 before the start of this coming influenza season, and will partner 509 after release of the VX 509 Phase 2 data in the second half of this year. All these are catalysts that will likely push the stock price even higher.....Comments about recent insider sales were even discussed....Leiden's answers sounded positive for the future of Vertex investors.....Ian Smith is wanting to stay on at Vertex, even after selling 90% of his options for $60 million because he knows future option packages will be worth even more as the company conitinues to execute it's business plan, and bring it's pipeline of drugs to market. Enjoy the ride.......

    Sentiment: Strong Buy

97.09Aug 26 4:00 PMEDT